The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease
Open accessAbstract
Cerebral white matter lesions (WML) encompass axonal loss and demyelination, and the pathogenesis is assumed to be small vessel disease (SVD)-related ischemia. However, WML may also result from the activation of Wallerian degeneration as a consequence of cortical Alzheimer's disease (AD) pathology, i.e. hyperphosphorylated tau (HPτ) and amyloid-beta (Aβ) deposition. WML seen in AD have a posterior predominance compared to non-demented individuals but it is unclear whether the pathological and molecular signatures of WML differ between these two groups. We investigated differences in the composition and aetiology of parietal WML from AD and non-demented controls. Parietal WML tissue from 55 human post-mortem brains (AD, n = 27; non-demented controls, n = 28) were quantitatively assessed for axonal loss and demyelination, as well as for cortical HPτ and Aβ burden and SVD. Biochemical assessment included Wallerian degeneration protease calpain and the myelin-associated glycoprotein (MAG) to proteolipid protein (PLP) ratio (MAG:PLP) as a measure of hypoperfusion. WML severity was associated with both axonal loss and demyelination in AD, but only with demyelination in controls. Calpain was significantly increased in WML tissue in AD, whereas MAG:PLP was significantly reduced in controls. Calpain levels were associated with increasing amounts of cortical AD-pathology but not SVD. We conclude that parietal WML seen in AD differ in their pathological composition and aetiology compared to WML seen in aged controls: WML seen in AD may be associated with Wallerian degeneration that is triggered by cortical AD-pathology, whereas WML in aged controls are due to ischaemia. Hence, parietal WML as seen on MRI should not invariably be interpreted as a surrogate biomarker for SVD as they may be indicative of cortical AD-pathology, and therefore, AD should also be considered as the main underlying cause for cognitive impairment in cases with parietal WML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“Additional neuropathological scoring of Lewy body pathology [9, 42], vascular pathology contribution to cognitive impairment (vascular impairment neuropathological guidelines (VCING)) [53], TDP-43 inclusions [30] and CAA [46] was performed.”
BackgroundDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Self-citation
Cited by
White matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes
Nasrabady, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0515-3 · Cited by 723
Oligodendrocytes in development, myelin generation and beyond
Kuhn, S., Gritti, L., Crooks, D., & Dombrowski, Y. (2019) · Cells · doi:10.3390/cells8111424 · Cited by 625
“White matter pathology is a characteristic of Alzheimer’s disease (AD), however oligodendrocyte death and demyelination are believed to occur secondary to neurodegeneration [177].”
BackgroundAlber, J., Alladi, S., Bae, H., Barton, D. A., Beckett, L. A., Bell, J. M., Berman, S. E., Biessels, G. J., Black, S. E., Bos, I., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.001 · Cited by 443
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Elahi, F. M., Casaletto, K. B., La Joie, R., Walters, S. M., Harvey, D., Wolf, A., Edwards, L., Rivera‐Contreras, W., Karydas, A., Cobigo, Y., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.004 · Cited by 255
Self-citationDysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies
Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183
“ever, the existing evidence is inconsistent, with some studies describing an intact endothelial layer even in severe SVD(9,79,80,124) and white matter lesions occurring secondary to cortical AD pathology.(125) At DYSFUNCTION OF THE BLOOD–BRAIN BARRIER IN ALZHEIMER’S DISEASE 7 of 12”
ResultSelf-citationWhite matter hyperintensity topography in Alzheimer's disease and links to cognition
Garnier‐Crussard, A., Bougacha, S., Wirth, M., Dautricourt, S., Sherif, S., Landeau, B., Gonneaud, J., De Flores, R., de la Sayette, V., Vivien, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12410 · Cited by 170
White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution
Garnier‐Crussard, A., Cotton, F., Krolak‐Salmon, P., & Chételat, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13057 · Cited by 139
Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions
Strain, J. F., Smith, R. X., Beaumont, H., Roe, C. M., Gordon, B. A., Mishra, S., Adeyemo, B., Christensen, J. J., Su, Y., Morris, J. C., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005864 · Cited by 97
Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Wang, Y.-L., Chen, W., Cai, W.-J., Hu, H., Xu, W., Wang, Z.-T., Cao, X.-P., Tan, L., Yu, J.-T., & Initiative, A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191005 · Cited by 92
Extracellular Vesicles of Alzheimer’s Disease Patients as a Biomarker for Disease Progression
Aharon, A., Spector, P., Ahmad, R. S., Horrany, N., Sabbach, A., Brenner, B., & Aharon-Peretz, J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02013-1 · Cited by 90
Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns
Pålhaugen, L., Sudre, C. H., Tecelao, S., Nakling, A., Almdahl, I. S., Kalheim, L. F., Cardoso, M. J., Johnsen, S. H., Rongve, A., Aarsland, D., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20957604 · Cited by 79
Rizvi, B., Lao, P. J., Chesebro, A. G., Dworkin, J. D., Amarante, E., Beato, J. M., Gutierrez, J., Zahodne, L. B., Schupf, N., Manly, J. J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25166 · Cited by 79
Weaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
Walter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1929-5 · Cited by 65
Tse, K., Cheng, A., Ma, F., & Herrup, K. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.010 · Cited by 56
Association of small vessel disease with tau pathology
Kapasi, A., Yu, L., Petyuk, V., Arfanakis, K., Bennett, D. A., & Schneider, J. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02397-x · Cited by 55
“Notably, our findings between WMH and elevated tau burden corroborate other neuroimaging-pathological studies that report similar findings [24, 39].”
BackgroundResultWhite matter hyperintensities are associated with subthreshold amyloid accumulation
Moscoso, A., Rey-Bretal, D., Silva-Rodríguez, J., Aldrey, J. M., Cortés, J., Pías-Peleteiro, J., Ruibal, Á., & Aguiar, P. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116944 · Cited by 49
Huynh, K., Piguet, O., Kwok, J., Dobson-Stone, C., Halliday, G. M., Hodges, J. R., & Landin-Romero, R. (2021) · Neurology · doi:10.1212/wnl.0000000000011638 · Cited by 43
Biesbroek, J. M., Coenen, M., DeCarli, C., Fletcher, E. M., Maillard, P. M., Initiative, A. D. N., Barkhof, F., Barnes, J., Benke, T., Chen, C. P. L. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13765 · Cited by 38
Self-citationRegional associations of white matter hyperintensities and early cortical amyloid pathology
Lorenzini, L., Ansems, L. T., Lopes Alves, I., Ingala, S., Vállez García, D., Tomassen, J., Sudre, C., Salvadó, G., Shekari, M., Operto, G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac150 · Cited by 36
White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease
Tian, J., Raghavan, S., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Gebre, R. K., Graff-Radford, J., Schwarz, C. G., Lowe, V. J., Kantarci, K., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207250 · Cited by 29
Kaskikallio, A., Karrasch, M., Koikkalainen, J., Lötjönen, J., Rinne, J. O., Tuokkola, T., Parkkola, R., & Grönholm-Nyman, P. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000506124 · Cited by 28
Newton, P., the BIOCARD Research Team, Tchounguen, J., Pettigrew, C., Lim, C., Lin, Z., Lu, H., Moghekar, A., Albert, M., & Soldan, A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220846 · Cited by 23
Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease
Nichols, J. B., Malek-Ahmadi, M., Tariot, P. N., Serrano, G. E., Sue, L. I., & Beach, T. G. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa160 · Cited by 22
Cha, W.-J., Yi, D., Ahn, H., Byun, M. S., Chang, Y. Y., Choi, J.-M., Kim, K., Choi, H., Jung, G., Kang, K. M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01417-8 · Cited by 20
Yilmaz, S. N., Steiner, K., Marksteiner, J., Faserl, K., Villunger, M., Sarg, B., & Humpel, C. (2024) · Biomolecules · doi:10.3390/biom14101326 · Cited by 9
Tse, K.-H., Cheng, A., Yeung, S. H.-S., Ng, J.-N., Cheng, G. W.-Y., Wang, Q., Zhu, B., Cui, Y., Jiang, L., Kofler, J., et al. (2021) · doi:10.1101/2021.01.22.20245217 · Cited by 2
“Indeed, white matter hyperintensities (periventricular leukodystrophy), suggestive of myelin abnormalities, are detectable in A-T patients as early as 17 months of age [33-35].”
BackgroundKasahara, H., Ikeda, M., Makioka, K., Nakamura, T., Takahashi, R., Kawarabayashi, T., Sanada, E., Suto, T., Higuchi, T., Tsushima, Y., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251316516
Metadata
- Authors
- McAleese, K. E., Walker, L., Graham, S., Moya, E. L. J., Johnson, M., Erskine, D., Colloby, S. J., Dey, M., Martin-Ruiz, C., Taylor, J.-P., Thomas, A. J., McKeith, I. G., De Carli, C., & Attems, J.
- Venue
- Acta Neuropathologica
- Published
- 2017-06-21
- Volume
- 134
- Issue
- 3
- Pages
- 459-473
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2696960437
- Cited by
- 273
- References
- 72
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.